Fate Therapeutics, Inc. (FATE) News

Fate Therapeutics, Inc. (FATE): $85.31

0.23 (+0.27%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add FATE to Watchlist
Sign Up

Industry: Biotech


Ranked

of 499

in industry

Filter FATE News Items

FATE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

FATE News Highlights

  • 500 - Internal server error
  • Over the past 13 days, the trend for FATE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest FATE News From Around the Web

Below are the latest news stories about Fate Therapeutics Inc that investors may wish to consider to help them evaluate FATE as an investment opportunity.

Earnings Preview: Fate Therapeutics (FATE) Q2 Earnings Expected to Decline

Fate Therapeutics (FATE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 28, 2021

Did You See What Cathie Wood Bought on Wednesday?

ARK Invest added to its stakes in DraftKings, Fate Therapeutics, and Zoom Video, all of which are trading well below their recent peaks.

Yahoo | July 22, 2021

Fate Therapeutics to Host Virtual Event Highlighting Interim Phase 1 Clinical Data from its Off-the-Shelf, iPSC-derived NK Cell Franchise for B-cell Lymphoma

SAN DIEGO, July 16, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that management will host a virtual event to highlight interim Phase 1 clinical data from its FT596 and FT516 programs for the treatment of relapsed / refractory B-cell lymphomas on August 19, 2021 at 4:30 p.m. ET. The live webcast of the presentation can be accessed under "E

Yahoo | July 16, 2021

Fate Therapeutics to Webcast Conference Call Reporting Second Quarter 2021 Financial Results

SAN DIEGO, July 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that the Company will host a conference call and live audio webcast on Wednesday, August 4, 2021 at 5:00 p.m. ET to report its second quarter 2021 financial results and provide a corporate update. In order to participate in the conference call, please dial 800-773-2954 (toll

Yahoo | July 15, 2021

Hedge Funds Have Never Been This Bullish On Fate Therapeutics Inc (FATE)

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 866 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]

Yahoo | June 28, 2021

7 Stocks to Buy Now if You’re Feeling Greedy While Others Are Fearful

Stock markets run on fear and greed in the short term.

Tezcan Gecgil on InvestorPlace | June 24, 2021

Fate Therapeutics Appoints Mark Plavsic, DVM, PhD, RAC as Chief Technical Officer

SAN DIEGO, June 15, 2021 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that Mark Plavsic, DVM, PhD, RAC has been appointed Chief Technical Officer. Dr. Plavsic brings over 20 years of broad technical excellence in global biopharmaceutical operations, having led teams in the commercial-scale cGMP manufacture and distribution, as well as the clinical-stage process, assay, and formulation development, of complex biologics. As Chief Technical Officer, Mark will oversee the Companys manufacturing, technical, and supply chain operations.

Intrado Digital Media | June 15, 2021

Heres Why FATEs Stock Priced Popped

Investors Alley Heres Why FATEs Stock Priced Popped FATEs stock price was higher on Friday because Fate Therapeutics (FATE) highlighted positive interim data from its study of FT516 in combination with Rituximab for B-cell Lymphoma. FT516 is the Companys universal, off-the-shelf natural killer (NK) cell product candidate derived from a clonal master induced pluripotent stem cell (iPSC) line engineered with a novel high-affinity, [] Heres Why FATEs Stock Priced Popped Ian Cooper

Investors Alley | June 8, 2021

BMO Capital Stick to Their Hold Rating for Fate Therapeutics By Investing.com

BMO Capital Stick to Their Hold Rating for Fate Therapeutics

Investing.com | June 7, 2021

Oppenheimer Stick to Their Buy Rating for Fate Therapeutics By Investing.com

Oppenheimer Stick to Their Buy Rating for Fate Therapeutics

Investing.com | June 6, 2021


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6893 seconds.